A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer: a Single-center, Open-label, Randomized Controlled Trial
Latest Information Update: 14 Mar 2024
Price :
$35 *
At a glance
- Drugs Camrelizumab (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- 05 Mar 2024 Status changed from recruiting to suspended (difficulty in enrolling participants).
- 09 Aug 2022 Status changed from not yet recruiting to recruiting.
- 15 Apr 2022 Planned initiation date changed from 1 Jan 2022 to 1 Jul 2022.